Trials / Completed
CompletedNCT03984110
One Year Trial Evaluating Safety of Ozurdex With Eylea
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Texas Retina Associates · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
Detailed description
In this study, the investigators aim to compare the effects of combined use of intravitreal injections of Ozurdex every three3 months and monthly Eylea/aflibercept to monthly intravitreal injections of aflibercept alone as measured by improvement in central subfield thickness from baseline at Week 48 in eyes with center-involving Diabetic Macular Edema and best-corrected visual acuity of 20/40 or worse
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozurdex | Intravitreal injection |
| DRUG | Eylea | Intravitreal injection |
Timeline
- Start date
- 2019-06-11
- Primary completion
- 2022-10-27
- Completion
- 2022-10-27
- First posted
- 2019-06-12
- Last updated
- 2024-04-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03984110. Inclusion in this directory is not an endorsement.